Skip to main content

Publications

Found 181 results
Author Title [ Year(Asc)]
2013
Seuc A, Peregoudov A, Betrán A, Gulmezoglu A. Intermediate outcomes in randomized clinical trials: an introduction. Trials. 2013;14:78.  (478.57 KB)
Bickford C, Magee LA, Mitton C, Kruse M, Synnes A, Sawchuck D, et al.. Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res. 2013;13:527.  (2 MB)
Firoz T, Chou D, von Dadelszen P, Agrawal P, Vanderkruik R, Tunçalp Ö, et al.. Measuring maternal health: focus on maternal morbidity. Bull World Health Organ. 2013;91(10):794-6.  (660.26 KB)
Payne BA, Hodgson S, Hutcheon J, Joseph KS, Li J, Lee T, et al.. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8.  (85.31 KB)
Lalani S, Firoz T, Magee LA, Sawchuck D, Payne BA, Gordon R, et al.. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223.  (529.81 KB)
von Dadelszen P, Sawchuck D, Hofmeyr J, Magee LA, Bracken H, Mathai M, et al.. PRE-EMPT (PRE-eclampsia-Eclampsia Monitoring, Prevention and Treatment): A low and middle income country initiative to reduce the global burden of maternal, fetal and infant death and disease related to pre-eclampsia. Pregnancy Hypertens. 2013;3(4):199-202.  (183.96 KB)
Magee LA, von Dadelszen P. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013;(4):CD004351.  (447.63 KB)
De Silva D, Halstead A, Côté A-M, Sabr Y, von Dadelszen P, Magee LA. Random urine albumin:creatinine ratio in high-risk pregnancy - Is it clinically useful?. Pregnancy Hypertens. 2013;3(2):112-4.  (189.28 KB)
Staff A, Benton S, von Dadelszen P, Roberts J, Taylor R, Powers R, et al.. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61(5):932-42.  (529.57 KB)
De Silva D, Halstead A, Côté A-M, Sabr Y, von Dadelszen P, Magee LA. Unexpected random urinary protein:creatinine ratio results-limitations of the pyrocatechol violet-dye method. BMC Pregnancy Childbirth. 2013;13:152.  (834.74 KB)
Bell M, Roberts J, Founds S, Jeyabalan A, Terhorst L, Conley Y. Variation in endoglin pathway genes is associated with preeclampsia: a case-control candidate gene association study. BMC Pregnancy Childbirth. 2013;13:82.  (404.09 KB)
2011
Kozic J, Benton S, Hutcheon J, Payne BA, Magee LA, von Dadelszen P. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004.  (280.12 KB)
Tsigas E, Magee LA. Advocacy organisations as partners in pre-eclampsia progress: patient involvement improves outcomes. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):523-36.  (438.09 KB)
Payne BA, Magee LA, von Dadelszen P. Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):449-62.  (178.71 KB)
Magee LA, von Dadelszen P, Allen V, Ansermino JM, Audibert F, Barrett J, et al.. The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120.  (322.85 KB)
Magee LA, Sawchuck D, Synnes A, von Dadelszen P, Basso M, Crane J, et al.. Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada. 2011;33(5):516 - 529.  (298.54 KB)
Millman A, Payne BA, Qu Z, M Douglas J, Hutcheon J, Lee T, et al.. Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714.  (383.37 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
von Dadelszen P, Payne BA, Li J, Ansermino JM, F Pipkin B, Côté A-M, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.  (201.46 KB)
Firoz T, Sanghvi H, Merialdi M, von Dadelszen P. Pre-eclampsia in low and middle income countries. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):537-48.  (309.47 KB)
Laskin S, Payne BA, Hutcheon J, Qu Z, M Douglas J, Ford J, et al.. The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can. 2011;33(9):900-8.  (370.8 KB)
Magee LA, Lowe S, M Douglas J, Kathirgamanathan A. Therapeutics and anaesthesia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):477-90.  (187.9 KB)
Yen T-W, Payne BA, Qu Z, Hutcheon J, Lee T, Magee LA, et al.. Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can. 2011;33(8):803-809.  (269.78 KB)
2010
Steegers E, von Dadelszen P, Duvekot J, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-44.  (809.94 KB)
2008
Magee LA, Helewa M, Rey E. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3 Suppl):S1-S2.  (1.73 MB)

Pages